$ABBV

AbbVie (ABBV) has integrated Iambic's AI platform, Enchant v3, into its small-molecule drug discovery efforts. The multiyear deal includes undisclosed upfront, milestone, and royalty payments. ABBV shares traded around $265, with GuruFocus estimating a 19.95% premium to its fair value of $220.98. The partnership's success hinges on the drug candidates it produces and their clinical trial progress.

Pfizer (PFE) and AbbVie (ABBV) are major U.S. drugmakers with diversified portfolios. Pfizer expects flat to slightly negative revenue growth in 2026 but aims for high single-digit CAGR from 2028. AbbVie anticipates 10.5% sales growth in 2026, driven by Skyrizi and Rinvoq. Both companies face patent expirations and competition. Analysts expect Pfizer's 2026 EPS to decrease 7.5%, while AbbVie's is projected to rise 40.5%.

AbbVie (ABBV) announced Health Canada approval for EPKINLY® (epcoritamab) to treat relapsed or refractory follicular lymphoma in adults. The approval is based on a Phase 3 study showing a 79% reduction in disease progression or death when combined with lenalidomide and rituximab. EPKINLY® is co-developed with Genmab.

AbbVie (ABBV) stock has risen significantly over the past decade, with a $10,000 investment growing to $61,425.56 with dividends reinvested. The company faces challenges like patent expirations and a high P/E ratio of 75. Analysts project three scenarios for the next decade: 6% annual return ($17,908), 9% return ($23,674), or 12% return ($31,058), depending on pipeline success and market conditions.

Iambic Therapeutics, backed by NVIDIA (NVDA) and Qatar Investment Authority, filed for a U.S. IPO and partnered with AbbVie (ABBV) for AI-driven drug discovery. AbbVie will use Iambic's AI platform for small-molecule programs, with a $40M upfront payment and up to $670M in milestones. NVIDIA benefits from increased demand for its compute resources. AbbVie reported Q2 2026 revenue of $16.99B, with strong hedge fund interest.

AbbVie Inc. stock reached an all-time high of $267.48, with a 21.29% increase over the past year and a 31% return in the last six months, according to InvestingPro. The company secured European approval for its drug Rinvoq and completed an $8.0 billion public offering for its Apogee acquisition. Analysts from Cantor Fitzgerald and BofA Securities maintained positive ratings and increased price targets.

The AI Structural Biology (AISB) Network, backed by Apheris, launched AISB Bind, a federated initiative with AbbVie, AstraZeneca, Bristol Myers Squibb, and Johnson & Johnson. The project aims to train an AI model to predict molecular binding for drug discovery, improving virtual screening and lead optimization. The model will be trained on proprietary data from the partners, with training beginning in September 2026 and expected to complete in early 2027.

Coca-Cola, PepsiCo, and AbbVie are highlighted for their strong dividend histories, recent guidance raises, and recession-resilient business models. Coca-Cola expects 5% organic revenue growth and 9-10% EPS growth. PepsiCo yields 4.31% and raised its dividend for 54 consecutive years. AbbVie, despite a high P/E, has a strong free cash flow yield and raised its full-year revenue guidance. All three are recommended for income investors.

AbbVie (NYSE:ABBV) reported Q2 revenue of $16.99B, up 10.2% YoY, beating estimates by 1.2%. Biogen (NASDAQ:BIIB) saw revenue rise 3.4% YoY, exceeding expectations by 12.1%. Myriad Genetics (NASDAQ:MYGN) reported a 10.5% YoY revenue decline, missing estimates by 8.2%. Gilead Sciences (NASDAQ:GILD) reported $7.80B in revenue, up 10.2% YoY, beating estimates by 6.2%. Moderna (NASDAQ:MRNA) reported $145M in revenue, up 2.1% YoY, surpassing expectations by 35.8%.

AbbVie (ABBV) paid $600M upfront for a Chinese asset, faces a House committee request for trial data, and bought 4.9% of ADARx for $78.5M. It also partnered with Iambic, receiving milestone payments and royalties.